Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: A time trade-off study

Health and Quality of Life Outcomes

Volumn 10, Issue , 2012, Pages

  Osborne, Richard H ^a   Dalton, Andrew ^b   Hertel, Judy ^c   Schrover, Rudolf ^c,d   Smith, Dell K ^c  

^a DEAKIN UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

^d PRIMA Consulting Group Pt Ltd   (Australia)

Author keywords

Antipsychotic; Long acting injection; Quality of life; Schizophrenia; Time trade off; Treatment interval

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; AUSTRALIA; CONSULTATION; EDUCATIONAL STATUS; FEMALE; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MEDICAL EXPERT; PHYSICIAN; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; RELAPSE; SCHIZOPHRENIA; AGED; COST OF ILLNESS; DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION; DRUG UTILIZATION; ECONOMICS; HEALTH SURVEY; INTERVIEW; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; PSYCHOLOGICAL ASPECT; SAMPLE SIZE; SOCIAL CLASS; STATISTICS; TIME; TREATMENT OUTCOME; UTILIZATION REVIEW;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; AUSTRALIA; COST OF ILLNESS; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION; FEMALE; HEALTH STATUS INDICATORS; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; QUALITY OF LIFE; SAMPLE SIZE; SCHIZOPHRENIA; SOCIAL CLASS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84859138459     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-10-35     Document Type: Article

References (23)

1. Association AP. Diagnostic and statistical manual of mental disorders: DSM-IV 1994, Washington (DC): American Psychiatric Association, 4.
2. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, Bertelsen A. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl 1992, 20:1-97.
3. McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2004, 2:13. 10.1186/1741-7015-2-13, 421751, 15115547.
4. Murray CJ, Lopez A. The global burden of disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020 1996, 990. Boston: Harvard University Press on behalf of the World Health Organization and the World Bank.
5. Carr VJ, Neil AL, Halpin SA, Holmes S, Lewin TJ. Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders Study. Aust N Z J Psychiatry 2003, 37(1):31-40. 10.1046/j.1440-1614.2003.01092.x, 12534654.
6. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999, 56(3):241-247. 10.1001/archpsyc.56.3.241, 10078501.
7. Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res 176(2-3):109-113.
8. Velligan DI, Lam F, Ereshefsky L, Miller AL. Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv 2003, 54(5):665-667. 10.1176/appi.ps.54.5.665, 12719495.
9. Haddad PM, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiatry Suppl 2009, 52:S20-28.
10. Johnson DA. Historical perspective on antipsychotic long-acting injections. Br J Psychiatry Suppl 2009, 52:S7-12.
11. Barnes TR, Shingleton-Smith A, Paton C. Antipsychotic long-acting injections: prescribing practice in the UK. Br J Psychiatry Suppl 2009, 52:S37-42.
12. Kulkarni J, Dalton A, Katz P, et al. A survey to assess pain associated with routine administration of intramuscular risperidone long-acting injection 2010, Australian Society for Psychiatric Research (ASPR): Bondi, Sydney.
13. Osborne RH, De Abreu Lourenco R, Dalton A, Houltram J, Dowton D, Joshua DE, Lindeman R, Ho PJ. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. Value Health 2007, 10(6):451-456. 10.1111/j.1524-4733.2007.00200.x, 17970927.
14. Dolan P. Output measures and valuation in health 2001, Oxford: Oxford University Press.
15. Torrance GW. Utility measurement in healthcare: the things I never got to. Pharmacoeconomics 2006, 24(11):1069-1078. 10.2165/00019053-200624110-00004, 17067192.
16. Australian Bureau of Statistics Population by Age and Sex, Australian States and Territories 2009, Canberra: Australian Bureau of Statistics, Australian Bureau of Statistics.
17. Wyrwich KW, Tierney WM, Babu AN, Kroenke K, Wolinsky FD. A comparison of clinically important differences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease. Health Serv Res 2005, 40(2):577-591. 10.1111/j.1475-6773.2005.0l374.x, 1361158, 15762908.
18. Briggs A, Wild D, Lees M, Reaney M, Dursun S, Parry D, Mukherjee J. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes 2008, 6:105. 10.1186/1477-7525-6-105, 2613374, 19040721.
19. Szende A, Schaefer C, Goss TF, Heptinstall K, Knight R, Lubbert M, Deschler B, Fenaux P, Mufti GJ, Killick S, et al. Valuation of transfusion-free living in MDS: results of health utility interviews with patients. Health Qual Life Outcomes 2009, 7:81. 10.1186/1477-7525-7-81, 2746210, 19737399.
20. Salkeld G, Cameron ID, Cumming RG, Easter S, Seymour J, Kurrle SE, Quine S. Quality of life related to fear of falling and hip fracture in older women: a time trade off study. BMJ 2000, 320(7231):341-346. 10.1136/bmj.320.7231.341, 27279, 10657327.
21. Nease RF, Kneeland T, O'Connor GT, Sumner W, Lumpkins C, Shaw L, Pryor D, Sox HC. Variation in patient utilities for outcomes of the management of chronic stable angina. Implications for clinical practice guidelines. Ischemic Heart Disease Patient Outcomes Research Team. JAMA 1995, 273(15):1185-1190. 10.1001/jama.1995.03520390045031, 7707625.
22. Froberg DG, Kane RL. Methodology for measuring health-state preferences-II: Scaling methods. J Clin Epidemiol 1989, 42(5):459-471. 10.1016/0895-4356(89)90136-4, 2732774.
23. Barber MN, Staples M, Osborne RH, Clerehan R, Elder C, Buchbinder R. Up to a quarter of the Australian population may have suboptimal health literacy depending upon the measurement tool: results from a population-based survey. Health Promot Int 2009, 24(3):252-261. 10.1093/heapro/dap022, 19531559.